Life sciences is pulling senior talent from technology, finance, and management consulting at rates we have never seen in our 15 years of executive search in the sector. In our 2024–2025 placement data, 23% of all VP-level and above life sciences placements went to candidates whose most recent role was outside the life sciences industry — up from 9% in 2019. The inflow is not random: it is concentrated in specific functions where the life sciences industry has genuine capability gaps that cross-industry hires are uniquely positioned to fill, and it is being driven by a combination of push factors in the source industries and pull factors in life sciences.
The push factors are straightforward: technology sector layoffs in 2022–2023 displaced thousands of senior professionals, many of whom are exploring industries with more durable growth profiles. Financial services professionals are looking for sectors with less cyclical volatility. Management consultants who spent years advising pharma and biotech clients are increasingly choosing to operate inside those companies rather than outside them. The pull factor is equally clear: the US life sciences industry is projected to grow at 7–9% annually through 2030, driven by an aging population, advances in biologics and gene therapy, and the integration of AI into drug discovery and clinical development.
Which skills transfer and which don’t
The skills that transfer most effectively into life sciences from adjacent industries fall into four categories:
From technology: Software engineering, data science, ML engineering, and product management skills are in high demand across pharma, biotech, and medical devices. A VP of Engineering from a tech company can lead digital transformation at a pharma company; a Head of Data Science from a financial services firm can build real-world evidence platforms at a biotech. The technical skills are directly transferable. What does not transfer: the expectation of rapid iteration, the assumption that software deployment cycles should be measured in days rather than months, and the engineering culture of “move fast and break things” that is antithetical to the life sciences regulatory environment.
From finance: Financial modeling, P&L management, M&A due diligence, and investor relations skills translate directly to CFO, VP of Finance, and business development roles in life sciences. The financial complexity of drug development — including clinical trial cost modeling, reimbursement economics, and equity financing at multiple development stages — rewards professionals with deep financial sophistication. What does not transfer: the assumption that financial metrics alone drive decisions. Life sciences decision-making involves scientific, regulatory, and clinical considerations that financial professionals must learn to weigh alongside economic ones.
From consulting: Strategic analysis, organizational design, and program management skills are valuable in life sciences strategy, operations, and commercial functions. McKinsey and BCG alumni are particularly well-represented in biopharma commercial leadership roles. What does not transfer: the consultant’s instinct to recommend rather than own. Life sciences companies hiring from consulting want executives who will make and live with decisions, not present options for others to decide.
Universal transfers: P&L ownership, team building, cross-functional leadership, and stakeholder management transfer across all industry boundaries. These “bedrock” leadership skills are the foundation of any successful cross-industry pivot.
The most accessible roles for career pivots
Not all life sciences roles are equally accessible to cross-industry hires. The roles with the lowest barrier to entry for experienced professionals from other sectors:
Chief Financial Officer / VP of Finance: Life sciences CFO roles are the most accessible senior pivot target. Financial leadership skills are directly transferable, and the industry’s complex financing structures (series rounds, milestone-based dilution, royalty monetization) reward sophisticated financial operators. A CFO with public-company experience from any sector can be competitive for biotech CFO roles, particularly at clinical-stage companies navigating their first IPO or secondary offering. Compensation: $350K–$550K total comp at clinical-stage biotechs; $500K–$900K at commercial-stage pharma.
Chief Information Officer / VP of IT: Pharma CIO roles are actively recruiting from technology companies, and the background transfer is relatively clean. The candidate needs to develop GxP compliance knowledge, but the core technology leadership skills are directly applicable. Compensation: $320K–$520K total comp at mid-size pharma; $480K–$780K at top-20 pharma.
VP of Commercial / Head of Marketing: Consumer-facing marketing and commercial leadership from CPG, technology, and financial services can translate to life sciences commercial roles, particularly for candidates who are willing to invest 6–12 months learning pharmaceutical market access, payer dynamics, and the regulatory constraints on life sciences marketing (OPDP compliance, fair balance requirements). Compensation: $340K–$500K total comp at mid-size biotech; $450K–$750K at large pharma.
VP of Data Science / Head of AI: The highest-demand pivot role. Technology sector data science leaders are being recruited aggressively by pharma and biotech companies building computational capabilities. Compensation: $280K–$450K at biotech; $380K–$650K at large pharma.
The roles that are not accessible without life sciences background: VP of Regulatory Affairs, VP of Clinical Development, Chief Medical Officer, Head of CMC, and VP of Medical Affairs. These roles require deep domain expertise that cannot be acquired through cross-industry transfer, regardless of the candidate’s seniority or general leadership capability.
Credential gaps and how to close them
The most common credential gap for cross-industry pivots into life sciences is regulatory literacy. Even for roles that don’t require regulatory expertise (CFO, CIO, VP of Commercial), hiring committees at life sciences companies will evaluate whether a cross-industry candidate demonstrates baseline understanding of the regulatory environment that governs the industry. A CFO candidate who cannot articulate how FDA approval timelines affect financial planning, or a CIO candidate who has never heard of 21 CFR Part 11, will be screened out regardless of their functional qualifications.
Practical steps to close the credential gap: industry-specific coursework through organizations like the Drug Information Association (DIA) or the Regulatory Affairs Professionals Society (RAPS) provides foundational regulatory knowledge. Advisory board positions at life sciences companies provide exposure and credibility. Fractional or consulting engagements with biotech or pharma companies provide hands-on experience that can be referenced in interviews. In our experience, the minimum credential-building period for a serious cross-industry pivot is 6–12 months of deliberate industry exposure before beginning an active search.
Compensation expectations for pivots
The compensation reality for cross-industry pivots into life sciences is nuanced. Professionals coming from technology will typically experience a 15–30% reduction in total compensation, driven primarily by lower equity values at most life sciences companies compared to tech. Professionals coming from financial services will typically experience a 5–15% reduction at the VP level but may see comparable or higher compensation at the C-suite level, where biopharma CEO and CFO packages are competitive with financial services equivalents. Professionals coming from management consulting will typically experience a 10–20% increase in total compensation, because consulting compensation at the Director and VP-equivalent levels is generally below what life sciences companies pay for comparable operational leadership.
The equity component deserves specific attention. Clinical-stage biotech equity can be enormously valuable if the company achieves regulatory milestones, but it is also high-risk: approximately 90% of drugs in clinical development fail, and the equity associated with failed programs has no value. Professionals accustomed to liquid public-company equity from tech or finance need to adjust their expectations for the risk profile of biotech equity. The professionals who thrive financially in life sciences pivots are those who join companies with late-stage clinical assets (Phase III or NDA/BLA stage) where the risk-adjusted equity value is more predictable.
The practical pivot playbook
For senior professionals from tech, finance, or consulting who are seriously evaluating a pivot into life sciences, a structured approach produces materially better outcomes than an opportunistic job search:
- Step 1: Identify your target sub-sector. Life sciences is not a monolithic industry. Pharmaceutical, biotech, medical devices, diagnostics, digital health, and contract research organizations have different talent needs, compensation structures, and cultural norms. Match your background to the sub-sector where your skills have the most direct application.
- Step 2: Build regulatory literacy. Invest 3–6 months in foundational regulatory education. DIA courses, RAPS certifications, and industry conferences provide the vocabulary and conceptual framework that life sciences hiring committees expect.
- Step 3: Create a bridge credential. An advisory role, a consulting engagement, or a board observer position at a life sciences company provides concrete evidence that you can operate in the sector. This is the single most effective way to overcome the “no life sciences experience” objection.
- Step 4: Work with a life sciences recruiter. The recruiter who knows your source industry cannot position you effectively in the target industry. A life sciences specialist can advocate for your transferable skills in the language that life sciences hiring committees respond to.
- Step 5: Target companies that are actively hiring cross-industry. Companies that have recently hired other cross-industry executives are more open to the pivot than companies that have never done so. Ask your recruiter which companies in your target sub-sector have a track record of successful cross-industry hires.
The honest assessment
A career pivot into life sciences from technology, finance, or consulting is genuinely achievable for senior professionals with strong functional skills and the willingness to invest in domain education. It is not a lateral move: it requires humility, deliberate credential-building, and the acceptance that some of your prior industry expertise will not translate directly. The professionals who make the pivot most successfully are those who approach it as a 12–18 month process rather than a reactive job search, and who are motivated by genuine interest in the life sciences mission rather than a simple desire to escape their current industry. For current compensation context across life sciences functions, see our 2026 Life Sciences Compensation Report.